Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Frank Takkinen maintains a Buy rating on Biolase (NASDAQ:BIOL) but lowers the price target from $1.5 to $0.4.
May 31, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lake Street analyst Frank Takkinen maintains a Buy rating on Biolase (NASDAQ:BIOL) but lowers the price target from $1.5 to $0.4.
The news of Lake Street analyst maintaining a Buy rating on Biolase is positive for the stock. However, the lowering of the price target from $1.5 to $0.4 indicates a reduced growth potential, which may offset the positive sentiment. Therefore, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100